Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2022-03-17 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民药业集团股份有限公司董事会议事规则
Governance Information Classification · 100% confidence The document is titled as the "Rules of Procedure for the Board of Directors" of a company, detailing the internal governance, rights, duties, meeting procedures, decision-making processes, and responsibilities of the board members. It includes sections on board composition, meeting convocations, voting procedures, committees, and disclosure obligations. There is no financial data, earnings information, or regulatory filings related to financial results. The content is focused on governance structure and board operations, which aligns with governance information rather than an announcement or report of financial results or management changes. The document is comprehensive and lengthy, indicating it is the actual governance rules document, not a brief announcement or summary. Therefore, the appropriate classification is Governance Information (CGR).
2022-03-17 Chinese
健民集团关于修改《公司章程》等内部制度部分条款的公告
Governance Information Classification · 95% confidence The document is a detailed announcement about amendments to the company's Articles of Association (公司章程), Shareholders' Meeting Rules (股东大会议事规则), and Board Meeting Rules (董事会议事规则). It includes specific changes to internal governance documents and rules, references to compliance with regulatory guidelines, and states that these amendments require shareholder approval. There is no financial data, earnings information, or audit content. The document focuses on governance structure and internal rules, which aligns with Governance Information filings. It is not a report publication announcement since it contains substantive content, not just a notice of report availability.
2022-03-17 Chinese
健民集团关于向中国人口福利基金会捐赠的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company regarding a charitable donation to the China Population Welfare Foundation. It details the donation amount, purpose, recipient, and approval process. There is no financial report, earnings data, management discussion, or regulatory filing content. The document is an announcement of a corporate social responsibility action, not a financial or regulatory report. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-03-17 Chinese
健民集团独立董事对第九届董事会第三十三次会议相关事项的独立董事意见
Board/Management Information Classification · 85% confidence The document is an independent opinion from the independent directors regarding several matters related to the company's board meeting, including the 2021 profit distribution plan, 2022 performance responsibility agreements, and the appointment of the 2022 audit firm. It references the submission of these matters to the shareholders' meeting for approval. The document is short (989 characters) and does not contain actual financial statements or detailed financial data. It is primarily an opinion and recommendation related to board and shareholder meeting matters, specifically about profit distribution and audit firm appointment. This fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Board/Management Information (MANG). However, since it is an independent opinion on board meeting matters and not a direct announcement of voting results, it aligns more closely with Board/Management Information (MANG).
2022-03-17 Chinese
健民集团第九届董事会第三十三次会议决公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 33rd meeting of the 9th Board of Directors of 健民药业集团股份有限公司. It includes voting results on various reports and proposals such as the 2021 President's Work Report, Board Work Report, Independent Directors' Report, Audit Committee Report, 2021 Financial Statements, Profit Distribution Plan, 2021 Annual Report, Internal Control Evaluation Report, financing proposals, asset write-offs, appointment of auditors, social responsibility report, amendments to company bylaws, and the scheduling of the 2021 Annual General Meeting. The document is a formal board meeting announcement with voting outcomes and references to reports that will be submitted to the shareholders' meeting for approval. It does not contain the full annual report or financial statements itself but rather the board's resolutions and voting results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3706 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2022-03-17 Chinese
健民药业集团股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告（众环专字(2022)0110092号）
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (special audit report) concerning the summary table of non-operating fund occupation and other related party fund transactions for the year 2021 of 健民药业集团股份有限公司. It is issued by a certified public accounting firm and includes detailed audit procedures and opinions on the summary table. The document contains audit findings and references to financial statements but is focused specifically on a special audit of related party transactions and non-operating fund usage, not a full annual report or interim report. It is a standalone audit report related to a specific issue, consistent with the definition of an Audit Report / Information (AR). The document length is 7571 characters, which is sufficient to contain substantive audit content rather than a mere announcement. Therefore, the appropriate classification is AR with high confidence.
2022-03-17 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.